Public Summary

Summary for ARTG Entry: 316310 DDR Prime Softgels

ARTG entry for	Medicine Listed
Sponsor	doTERRA Australia Pty Ltd
Postal Address	102 / 271 Wellington Road, Mulgrave, VIC, 3170 Australia
ARTG Start Date	9/04/2019
Product category	Medicine
Status	Active
Approval area	Listed Medicines

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1. DDR Prime Softgels

Product Type Single Medicine Product **Effective date** 11/04/2019

Permitted Indications

Traditionally used in Western herbal medicine to maintain/support general health and wellbeing
Traditionally used in Western herbal medicine to orexigenic/improve/promote healthy appetite
Traditionally used in Western herbal medicine to decrease/reduce/relieve colic (wind/gas pain)
Traditionally used in Western herbal medicine to decrease/reduce/relieve flatulence/carminative
Traditionally used in Western herbal medicine to decrease/reduce/relieve abdominal spasm
Traditionally used in Western herbal medicine to decrease/reduce/relieve symptoms of indigestion/dyspepsia
Traditionally used in Western herbal medicine to reduce occurrence of nausea/vomiting
Traditionally used in Western herbal medicine to reduce occurrence of nausea/vomiting
Traditionally used in Western herbal medicine to antiemetic/Decrease/reduce/relieve vomiting
Traditionally used in Western herbal medicine to decrease/reduce/relieve mild bronchial irritation
Traditionally used in Western herbal medicine to expectorant/clear respiratory tract mucous

Indication Requirements

Label statement: If symptoms persist, talk to your health professional.
Product presentation must not imply or refer to gastro oesophageal reflux disease.
Product presentation must not imply or refer to serious forms of respiratory disorders/diseases, such as: asthma, pneumonia, COAD, COPD, influenza.
Product presentation must not imply or refer to eating disorders.
Product presentation must only refer to mild bronchitis.

Standard Indications

No Standard Indications included on Record

Specific Indications

Warnings

No Warnings included on Record

Additional Product information

Pack Size/Poison information

Pack Size	**Poison Schedule**

Components

1. Formulation 1

Dosage Form	Capsule, soft
Route of Administration	Oral
Visual Identification	

Active Ingredients

Satureia hortensis	**19.4 mg**
Syzygium aromaticum	**21.34 mg**

Public Summary